Clinical Trial Update: A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial update evaluating GW679769 for effects on sleep and cognitive function in adults with primary insomnia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• GW679769

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sleep Initiation and Maintenance Disorders | Phase 2 | Status: COMPLETED